VOLITIONRX LTD (VNRX): Unregistered Sales of Equity Securities
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management X
How this was made
The 30-second read
Why it matters
The issuance adds ~0.8% to the outstanding share count, modestly diluting existing holders.
Market read
A routine financing event for a micro‑cap biotech with limited immediate market impact.
What to watch
Possible upcoming milestones that could make the newly issued shares more valuable.
Background
SEC Form 8‑K filing reporting unregistered sales of equity securities under a convertible note agreement.
Ticker impact
VolitionRx disclosed issuance of 220,264 and 553,097 shares to satisfy convertible note conversions, totaling $400k of new equity.
minor downward pressure due to dilution, limited upside.
The share count increase is small relative to market cap, but conversion may signal future financing needs.
Market effects
Limited impact on biotech sector; similar small-cap financing events are common.
No significant regional effect.
Minimal global relevance.
Counterpoint
Potential for upside if conversion indicates confidence in pipeline and future cash flow.
Key entities
- CompanyVolitionRx Ltd
Biotech firm issuing shares.
- InvestorLind Global Asset Management XII LLC
Holder converting notes into common stock.
